News
Here's Why Idera Pharmaceuticals, Inc. Is Surging Today
Shares of Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biotech advancing novel therapies for skin-related diseases, are getting a bump after the company presented trial results at....
Here's Why Allergan Stock Might Be an Incredible Bargain After Dropping 9.9% in August
Despite a stronger-than-expected second quarter earnings report, Allergan's (NYSE: AGN) two month long rally came to an abrupt halt in August with the stock losing 9.9% of its value, according to....
Why Biogen Stock Raced Higher In August
Biotech titan Biogen (NASDAQ: BIIB) saw its shares rise by 8.73% last month, according to data from S&P Global Market Intelligence. This healthy march northward was sparked by an encouraging....
BOIRON : Formulaire de déclaration mensuelle des droits de vote au 31 août 2017
Le 8 septembre 2017
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
Allergan's Patent Loophole Could Be a Huge Gift for Pfizer
The tribe has spoken.On Friday, Allergan (NYSE: AGN) announced that the Saint Regis Mohawk Tribe now owns all patents for blockbuster dry-eye disease drug Restatis. Both parties should win from....
Here's Why the Best Is Yet to Come for Cara Therapeutics, Inc.
By late June, Cara Therapeutics, Inc. (NASDAQ: CARA) stock had soared more than 175% year to date. Within a couple of weeks, however, many of those gains had been lost. Cara shares crashed after....
3 Reasons to Buy Allergan plc Stock Right Now
Allergan (NYSE: AGN) is one of the most underappreciated big pharma stocks on the market right now. That's the thought that occurred to me as I listened to Brent Saunders, Allergan's CEO, speak at....
Is Amicus Therapeutics Stock Still a Strong Buy?
According to data from S&P Global Market Intelligence, shares of rare-disease drugmaker Amicus Therapeutics (NASDAQ: FOLD) rose by 6.6% last month. Although the company did provide a bevy of....
Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors
Exelixis (NASDAQ: EXEL) was one of the top biotech stocks of 2016. It's also one of the best biotech stocks so far this year. However, Exelixis shares have pulled back in recent days, primarily....
2 Dividend Stocks You Can Buy and Hold Forever
If you'd like to park your money in stocks and monitor them as little as possible, you need to choose them extra carefully. There's no guarantee that even today's most successful companies won't....
Does Teva's Terrible Tumble Make Its Stock a Buy?
Disappointing financial results, a dividend cut, and reduced guidance have caused Teva Pharmaceutical Industries (NYSE: TEVA) shares to lose half their value in the past month. Can a restructuring....
CAR-T Mania: Could Juno Therapeutics Get Acquired Next?
Gilead Sciences (NASDAQ: GILD) recently acquired Kite Pharma (NASDAQ: KITE), but that doesn't mean an acquisition of Juno Therapeutics (NASDAQ: JUNO) is off the table. Juno Therapeutics'....
3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?
Every biotech company goes into a clinical study with great hopes -- and often great fears, as well. There's no guarantee that all will go well. All the time and money poured into an experimental....
ALPHA MOS : MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES A L'ASSEMBLEE GENERALE MIXTE DU 29 SEPTEMBRE 2017
Les actionnaires de la société Alpha MOS sont invités à participer à une assemblée générale mixte qui se tiendra le 29 septembre 2017 à 10 heures.
Au siège social de la société :
Immeuble Le....
Here's Why United Therapeutics Sank as Much as 10.8% Today
Shares of rare-disease specialist United Therapeutics (NASDAQ: UTHR) dropped nearly 11% today after the company announced that a phase 3 trial evaluating Orenitram in patients with pulmonary....
Why NewLink Genetics Is Soaring 37.5% Higher Today
After NewLink Genetics Corporation (NASDAQ: NLNK) updated data from its ongoing phase 2 trial of IDO inhibitor indoximod in advanced melanoma, shares in the immuno-oncology specialist shot higher....
2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August
Shares of Exelixis (NASDAQ: EXEL), a biotech company primarily focused on developing drugs to treat cancer, rallied more than $2 per share during the month of August, according to data from....
This Clear Catalyst Sent Valeant Pharmaceuticals Intl. Inc. 18% Lower in August
Shares of Valeant Pharmaceuticals (NYSE: VRX), a drugmaker that has predominantly grown via acquisitions over the years, plunged by 18% during August, according to data from S&P Global Market....
A Perfect Storm Cut Teva Pharmaceutical Industries's Stock in Half in August
Shares of Teva Pharmaceutical Industries (NYSE: TEVA), an Israeli-based developer of branded and generic drugs, imploded in August and lost 51% of its market cap, according to data from S&P....
The 5 Worst Reasons to Buy Marijuana Stocks
Chances are you'd struggle to find an industry that's been stronger over the trailing one-year period than legal marijuana. Cannabis research firm ArcView pegged North American legal weed growth....
Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc
Big drugmaker. High dividend yield. Promising new products. All three apply to AbbVie Inc. (NYSE: ABBV). They also all apply to GlaxoSmithKline plc (NYSE: GSK). But while AbbVie stock has achieved....
Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock
Bristol-Myers Squibb (NYSE: BMY) investors might have been just a bit worried on Wednesday. After all, the U.S. Food and Drug Administration (FDA) had just placed a partial clinical hold on three....
Why Intra-Cellular Therapies Is Surging Today
Shares of Intra-Cellular Therapies (NASDAQ: ITCI), a clinical-stage pharma company focused on diseases of the central nervous system, jumped more than 17% as of 3:15 p.m. EDT on Thursday. The....
Why Gene-Editing Pioneer Editas Skyrocketed 28.8% in August
Editas Medicine (NASDAQ: EDIT) is researching the use of gene editing to treat disease. After the company updated investors on its progress on Aug. 9, shares soared 18.8% last month, according to....
AbbVie Scores 2 Wins: 1 Threatens Regeneron
AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a victory against Coherus Biosciences (NASDAQ: CHRS) in a patent challenge and the release of positive late-stage trial....